Arkolith/Insider Trading/NRIX/Form 4

van Houte Hans

Chief Financial OfficerNurix Therapeutics, Inc. (NRIX) · full profile →Form 4 · filed May 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$233K
Net Open-Market Flow
-$233K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 5, 2026Sell(S)13K$16.58$223K38K
May 5, 2026Sell(S)582$17.18$10K38K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001817217-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML